Skip to main content
. 2022 Mar 10;66(4):e02192-21. doi: 10.1128/aac.02192-21

FIG 3.

FIG 3

(A) Bioluminescence induced over 7 days by isoniazid, moxifloxacin, and 22 in H37Rv containing a modified recA promoter that drives the expression of DNA damage-inducible genes. (B) Total luminescence produced over 7 days for each concentration of isoniazid, moxifloxacin, and 22. (C) MIC determinations for isoniazid, moxifloxacin, and 22 against H37Rv (RecA).